In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac

被引：0

作者：

Kateřina Ondrák Fialová ^{[1
]}

Lukáš Ondrák ^{[1
]}

Martin Vlk ^{[1
]}

Ján Kozempel ^{[1
]}

Kateřina Nováková ^{[2
]}

Zbyněk Nový ^{[3
]}

Katarína Hajduová ^{[3
]}

Marián Hajdúch ^{[3
]}

Miloš Petřík ^{[3
]}

Marek Pruszynski ^{[4
]}

Frank Bruchertseifer ^{[5
]}

Alfred Morgenstern ^{[6
]}

机构：

[1] Czech Technical University in Prague,Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering

[2] Institute of Organic Chemistry and Biochemistry of the CAS,European Commission

[3] Institute of Molecular and Translational Medicine,undefined

[4] Faculty of Medicine and Dentistry,undefined

[5] Palacký University,undefined

[6] Institute of Nuclear Chemistry and Technology,undefined

[7] NOMATEN Centre of Excellence,undefined

[8] National Centre for Nuclear Research,undefined

[9] Joint Research Centre,undefined

来源：

EJNMMI Radiopharmacy and Chemistry | / 10卷 / 1期

关键词：

HER2; Pertuzumab; Trastuzumab; Actinium-225; Targeted alpha therapy; SKOV-3; MDA-MB-231;

D O I：

10.1186/s41181-025-00337-8

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Evaluation of an Anti-HER2 Nanobody Labeled with 225AC for Targeted α-Particle Therapy of Cancer
Pruszynski, Marek
D'Huyvetter, Matthias
Bruchertseifer, Frank
Morgenstern, Alfred
Lahoutte, Tony
MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1457 - 1466
[2] 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy - an in vitro and in vivo evaluation
Rodak, Magdalena
Dekempeneer, Yana
Wojewodzka, Maria
Lahoutte, Tony
Bruchertseifer, Frank
Morgenstern, Alfred
D'Huyvetter, Matthias
Pruszynski, Marek
NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : S33 - S33
[3] Anti-HER2 antibody DOTA-pertuzumab conjugation and labelling studies with Ac-225
Fialova, K.
Ondrak, L.
Vlk, M.
Kozempel, J.
Pruszynski, M.
Bruchertseifer, F.
Morgenstern, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S655 - S655
[4] Anti HER2 Nanobody Labeled with 225Ac as a Potential Radiopharmaceutical for TRT
Pruszynski, M.
Cedrowska, E.
Radchenko, V.
John, K. D.
Bruchertseifer, F.
Morgenstern, A.
D'Huyvetter, M.
Lahoutte, T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S177 - S177
[5] Evaluation of 134Ce as a PET imaging surrogate for antibody drug conjugates incorporating 225Ac
Bailey, Tyler A.
Wacker, Jennifer N.
An, Dahlia D.
Carter, Korey P.
Davis, Ryan C.
Mocko, Veronika
Larrabee, John
Shield, Katherine M.
Lam, Mila Nhu
Booth, Corwin H.
Abergel, Rebecca J.
NUCLEAR MEDICINE AND BIOLOGY, 2022, 110 : 28 - 36
[6] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Alberto Ocaña
Eitan Amir
Atanasio Pandiella
Breast Cancer Research, 22
[7] In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
Pfannkuchen, Nina
Pektor, Stefanie
Miederer, Matthias
Roesch, Frank
JOURNAL OF NUCLEAR MEDICINE, 2018, 59
[8] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Ocana, Alberto
Amir, Eitan
Pandiella, Atanasio
BREAST CANCER RESEARCH, 2020, 22 (01)
[9] A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
Mohammadi, Mehdi
Jeddi-Tehrani, Mahmood
Golsaz-Shirazi, Forough
Arjmand, Mohammad
Bahadori, Tannaz
Judaki, Mohammad Ali
Shiravi, Fariba
Zare, Hengameh Ahmadi
Haghighat, Farzaneh Notash
Mobini, Maryam
Amiri, Mohammad Mehdi
Shokri, Fazel
FRONTIERS IN IMMUNOLOGY, 2021, 11
[10] In vitro and in vivo evaluation of bismuth-213 labeled anti-HER2 nanobodies
Dekempeneer, Y.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S57 - S58

← 1 2 3 4 5 →